AGILENT TECHNOLOGIES INC (A)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for A
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| A | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INCY | Independent Director | 66 | ["Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019","Chief Medical and Scientific Officer of the American Cancer Society from April 2007 to December 2018","Director of the Georgia Cancer Center at Grady Memorial Hospital from January 2002 to August 2007","Professor of hematology, oncology, medicine and epidemiology at Emory University from April 2001 to December 2018","Assistant director and senior investigator at the National Cancer Institute","Internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital","Experience serving as a director of other publicly held life sciences companies"] | ["Science and Technology"] | 2026 |
Biography sourced from the proxy statement filing.
Since 2019, Dr. Brawley has served as the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. From 2007 to 2018, he served as the Chief Medical and Scientific Officer at the American Cancer Society. He served as an Internist and Oncologist and Professor of Hematology, Oncology, Medicine and Epidemiology at Emory University from 2001 to 2018. Dr. Brawley has served on the board of directors of Incyte Corporation, a public biotechnology company, since September 2021, the board of directors of Lyell Immunopharma, Inc., a public biotechnology company, since April 2021, and the board of directors of PDS Biotechnology Corp, a public biotechnology company, since November 2020. Dr. Brawley brings to the Board scientific expertise and relevant insight into healthcare delivery through his current responsibilities in a leading large academic medical center. In addition, Dr. Brawley brings considerable public company director experience.